RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

McCoy, John; Goren, Andy; Cadegiani, Flávio Adsuara; Vaño-Galván, Sergio; Kovacevic, Maja; Situm, Mirna; Shapiro, Jerry; Sinclair, Rodney; Tosti, Antonella; Stanimirovic, Andrija; Fonseca, Daniel; Dorner, Edinete; Onety, Dirce Costa; Zimerman, Ricardo Ariel; Wambier, Carlos Gustavo

doi:10.3389/fmed.2021.668698

ORIGINAL RESEARCH article

Front. Med. , 19 July 2021

Sec. Infectious Diseases – Surveillance, Prevention and Treatment

Volume 8 - 2021 | https://doi.org/10.3389/fmed.2021.668698

This article is part of the Research Topic Coronavirus Disease (COVID-19): Pathophysiology, Epidemiology, Clinical Management and Public Health Response, Volume II View all 165 articles

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

A retraction of this article was approved in:

Retraction: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
1. Read retraction
Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
1. Read general commentary

$\r\nJohn McCoy$ John McCoy¹^*

Andy Goren¹

Flávio Adsuara Cadegiani^1,2

Sergio Vaño-Galván³

Maja Kovacevic⁴

Mirna Situm⁴

Jerry Shapiro⁵

Rodney Sinclair⁶

Antonella Tosti⁷

Andrija Stanimirovic⁸

Daniel Fonseca⁹

Edinete Dorner⁹

Dirce Costa Onety⁹

Ricardo Ariel Zimerman¹⁰

Carlos Gustavo Wambier¹¹

¹Applied Biology, Inc. Irvine, CA, United States
²Department of Endocrinology, Corpometria Institute, Brasilia, Brazil
³Dermatology Department, Ramón y Cajal Hospital, Madrid, Spain
⁴Department of Dermatology and Venereology, University Hospital Center “Sestre Milosrdnice”, Zagreb, Croatia
⁵Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, United States
⁶Sinclair Dermatology, Melbourne, VIC, Australia
⁷Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, United States
⁸School of Medicine, European University Cyprus, Nicosia, Cyprus
⁹Intensive Care Unit, Samel Hospital, Manaus, Brazil
¹⁰Hospital da Brigada Militar, Porto Alegre, Brazil
¹¹Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, United States

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: McCoy J, Goren A, Cadegiani FA, Vaño-Galván S, Kovacevic M, Situm M, Shapiro J, Sinclair R, Tosti A, Stanimirovic A, Fonseca D, Dorner E, Onety DC, Zimerman RA and Wambier CG (2021) Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front. Med. 8:668698. doi: 10.3389/fmed.2021.668698

Received: 17 February 2021; Accepted: 11 June 2021;
Published: 19 July 2021; Retracted: 10 June 2022.

Edited by:

Zisis Kozlakidis, International Agency For Research on Cancer (IARC), France

Reviewed by:

Chao Ren, First Hospital Affiliated to the Chinese PLA General Hospital, China
Olufemi Babalola, ECWA Bingham University, Nigeria

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good